...
首页> 外文期刊>European journal of gastroenterology and hepatology >A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study
【24h】

A combination of faecal tests for the detection of colon cancer: A new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study

机译:结合粪便检查以检测结肠癌:适当选择转诊至结肠镜检查的新策略?前瞻性多中心意大利研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Colonoscopy workload for endoscopy services in Western countries is increasing markedly because of the implementation of faecal occult blood-based mass screening programmes against colorectal cancer (CRC). We therefore explored the possibility of using a combination of faecal tests to prioritize the access to colonoscopy with criteria other than symptoms and/or time of referral. AIMS AND METHODS: We tested a combination of faecal tests [immunochemical faecal occult blood test (i-FOBT), M2-PK, calprotectin] as markers for advanced neoplasia in a selected series of patients requiring colonoscopy for the suspicion of CRC. All the tests were performed in a 1-day stool sample of patients aged 50-80 years, without any dietary restriction, before colonoscopy. RESULTS: A total of 280 patients' stool single samples were analysed. Forty-seven patients had CRC and 85 patients had one or more advanced adenoma(s) at colonoscopy/histology. CRCs were associated with a highly significant increase (P<0.001) in faecal tumour M2-PK (mean 24.2 kU/l), which correlated with Dukes' staging. For CRC detection, i-FOBT was the test with the highest specificity and positive predictive value (0.89 and 0.53), whereas M2-PK had the highest sensitivity and negative predictive value (0.87 and 0.96). Calprotectin showed performance similar to M2-PK in terms of sensitivity and negative predictive value (0.93), but had lower specificity (0.39). The best combination of tests to predict the risk of CRC in this series was i-FOBT+M2-PK, as in patients showing positivity to both markers, the risk of cancer was as high as 79%. CONCLUSION: The combination of i-FOBT and M2-PK is a sensitive tool in clinical practice for the appropriate management of waiting lists for colonoscopy, as it allows the classification of patients into different degrees of priority for investigation, according to their foreseeable risk of CRC.
机译:简介:由于实施了针对大肠癌(CRC)的粪便隐血性大众筛查计划,西方国家用于内窥镜检查服务的结肠镜检查工作量显着增加。因此,我们探讨了使用粪便检查的组合,以除症状和/或转诊时间以外的其他标准来优先进行结肠镜检查的可能性。目的和方法:我们在选定的一系列需要结肠镜检查以怀疑CRC的患者中测试了粪便检查(免疫化学粪便潜血检查(i-FOBT),M2-PK,钙卫蛋白)的组合作为晚期肿瘤的标志物。在结肠镜检查之前,所有测试均在年龄为50-80岁,无任何饮食限制的患者的1天大便样本中进行。结果:共分析了280例患者的粪便单样本。在结肠镜检查/组织学检查中,有47例CRC患者和85例患有一种或多种晚期腺瘤。 CRC与粪便肿瘤M2-PK的高度显着增加(P <0.001)(平均24.2 kU / l)相关,这与Dukes的分期相关。对于CRC检测,i-FOBT是具有最高特异性和阳性预测值(0.89和0.53)的测试,而M2-PK具有最高敏感性和阴性预测值(0.87和0.96)。钙卫蛋白在敏感性和阴性预测值(0.93)方面表现出与M2-PK相似的性能,但特异性较低(0.39)。在该系列中预测CRC风险的最佳测试组合是i-FOBT + M2-PK,因为对两种标记物均呈阳性的患者,癌症风险高达79%。结论:i-FOBT和M2-PK的组合在临床实践中是敏感的工具,可以适当地管理结肠镜检查的等待清单,因为它可以根据患者的可预见风险将其分为不同的优先研究等级。 CRC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号